Biovie is trading down 6.25% in pre-market at $1.20, and the reason for the decline remains unclear. - The price compares with the October 22 close of $1.28. - No clear company-specific announcement dated October 23 was found. Recent coverage focused on Phase 2 bezisterim findings presented earlier in the week, which does not establish a cause for the move. - Broader market indicators were mixed to lower, with no strong aligned move shown in the supplied figures.